Explore

Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Ionis Pharmaceuticals Announces 2026 Virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals Announces 2026 Virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals Announces 2026 Virtual Annual Meeting of Stockholders
Rapid Read Rapid Read
Researchers Focus on Reducing Chronic Disease to Enhance Longevity

Researchers Focus on Reducing Chronic Disease to Enhance Longevity

In the pursuit of extending human lifespan, researchers are emphasizing the importance of addressing chronic diseases such as heart disease, diabetes, and cancer. These conditions are major contributors to mortality and disability, particularly in older adults. Journalist Kara Swisher's series 'Kara Swisher Wants to Live Forever' explores medical advancements aimed at combating these diseases. Technologies like CRISPR gene editing and mRNA vaccines are being developed to prevent and treat chronic conditions. For instance, mRNA vaccines are entering clinical trials for diseases like HIV and cancer, showing promise in early studies. The focus is on achieving 'healthy longevity,' where individuals not only live longer but also maintain good health throughout their extended years.
Trendline Trendline
KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development

KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development

KROMATID Unveils Genomic Integrity Benchmarking at ASGCT 2026, Enhancing Cell Therapy Development
Trendline Trendline
BreezeBio Innovates Non-Viral Gene Delivery for Therapeutics

BreezeBio Innovates Non-Viral Gene Delivery for Therapeutics

BreezeBio Innovates Non-Viral Gene Delivery for Therapeutics
Trendline Trendline
BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics

BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics

BreezeBio Advances Non-Viral Gene Delivery Technology for Therapeutics
Rapid Read Rapid Read
FDA's New Pathway Aims to Expand Gene Therapy for Rare Disorders

FDA's New Pathway Aims to Expand Gene Therapy for Rare Disorders

The U.S. Food and Drug Administration (FDA) has introduced a new draft guidance called the Plausible Mechanism Pathway, aimed at enhancing the development of personalized gene-editing therapies for rare and ultra-rare disorders. This initiative is a response to the successful treatment of a rare metabolic disorder in a patient known as 'Baby KJ' using CRISPR technology. The guidance seeks to provide regulatory flexibility, allowing for the development of N-of-1 gene-editing therapies, which are tailored to individual patients. The FDA's approach suggests that substantial evidence of effectiveness for these therapies could be established through a single, well-controlled clinical investigation with confirmatory evidence. This move is part of a broader effort to increase the number of gene therapies available, with the potential to treat approximately 30 million individuals in the United States who suffer from rare disorders.
Rapid Read Rapid Read
FDA Appoints Szarama as Acting CBER Director Amid Leadership Changes

FDA Appoints Szarama as Acting CBER Director Amid Leadership Changes

Katherine Szarama has been appointed as the acting director of the FDA's Center for Biologics Evaluation and Research (CBER), following the end of Vinay Prasad's tumultuous tenure. Szarama, who previously served as Prasad's deputy, steps into the role as the FDA navigates leadership transitions. Prasad's tenure was marked by controversy, including the handling of Sarepta Therapeutics' gene therapy issues.
Rapid Read Rapid Read
Advancements in Non-Viral DNA Integration in Human T Cells Highlight Potential for Cancer Therapy

Advancements in Non-Viral DNA Integration in Human T Cells Highlight Potential for Cancer Therapy

Recent research has focused on the non-viral targeted integration of large DNA sequences into primary human T cells without the need for double-stranded DNA breaks. This method, which avoids the use of viral vectors, represents a significant advancement in the field of gene therapy, particularly for cancer treatment. The study highlights the potential of using CRISPR-associated transposases to achieve precise DNA integration, which could enhance the safety and efficacy of T-cell therapies. This approach aims to mitigate the risks associated with traditional viral vector methods, such as insertional mutagenesis and immune responses. The research underscores the potential for developing more effective and safer CAR T-cell therapies, which are engineered to target and destroy cancer cells.
Trendline Trendline
Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Trial for Chronic Pain